Strategic Intelligence Briefing  ·  Prepared for the GlycoSyn leadership teamIndependent research by BioCreative Strategies
BioCreative Strategies
For Anushka Jayasuriya & the GlycoSyn commercial team

A custom commercial system, built for GlycoSyn in three months.

A custom React app, your own SQL database, a knowledge graph of every pharma buyer in your CDMO orbit, multi-channel outreach across LinkedIn and email — and a foundation we can extend into strategic-selling pipeline as your sales motion matures.

Everything on this page is built specifically for GlycoSyn. The intelligence is live. The infrastructure is ready to deploy.

The full BioCreative engagement

Three waves. One commercial engine. Yours at the end.

The BioCreative Launch program builds GlycoSyn's complete commercial system in three overlapping waves — research and knowledge graph first, then the database + UX + sending infrastructure, then live activation across LinkedIn and email. Every artifact is yours to keep.

Wave A — Month 1

Intelligence + knowledge graph

Deep market research, ICP definition, account universe, competitive landscape, news ingestion. The knowledge graph that everything else runs on — populated with real GlycoSyn-relevant signals from day one.

Wave B — Month 1–2

Database, UX, sending infrastructure

Postgres database, custom React dashboard, virtual server provisioned, sending domains warmed, third-party APIs integrated, enrichment pipeline live. Built in GlycoSyn's brand and behind your team's login. Owned at handoff.

Wave C — Month 2–3

Activation across LinkedIn + Email

Multi-channel outreach live. Custom messages generated against your knowledge graph, sent through warmed infrastructure on a dedicated IP. Reply classification active. Pipeline reporting live in your UX. Meetings booked.

Every section below dives into a piece of this. What we build, how it works, and proof it's already running.

Your app build — what you own

The core stack we build, harden, and hand back.

A complete commercial system — custom React UX, Postgres database, backend automation, and hardened sending infrastructure — built in GlycoSyn's brand. Cancel anytime and take everything with you: the app, the database, the server, the code. No lock-in, no black box.

Custom UX

Your React App

Accounts, campaigns, news, outreach — one operator UX in your brand, behind secure login. Hosted on your virtual server. Transferable to any host.

Database

Postgres / Supabase

SQL database storing every pharma and biotech contact, every CPhI lead, every campaign interaction. Real-time, exportable, API-accessible. Every table, every row — yours.

Hosting

Virtual Server

The backend hub for everything we build — APIs, automations, news ingestion, channel connections all run here. Available for migration if needed.

Code & IP

GitHub

Every line of code — front-end, back-end, schema, knowledge graphs, data pipelines, agent harnesses, prompts. All in your repo, all yours to transfer.

Backend

n8n + Custom Harnesses

Edge functions, coordinated n8n flows, custom Python and TypeScript harnesses — all executing on your server. The automation layer that keeps everything running.

LinkedIn

HeyReach

Multi-account LinkedIn automation for pre-event outreach and post-CPhI follow-up. Your workspace, your rep accounts, your campaign data.

Email

EmailBison

Warmed sending infrastructure on a dedicated BioCreative IP. Your domains, your mailboxes.

Every piece above becomes GlycoSyn's property at handoff. The UX, database, server, and GitHub repo form a transferable unit — move it anywhere, run it independently.

Our backend research engine — what powers your database

How we fill your knowledge graph.

These are the tools and feeds we operate continuously to populate GlycoSyn's database with classified accounts, enriched contacts, scored news, and live intelligence. You don't license these individually — we run them and the structured output lands in your database, ready to power messages, the live newsfeed, and your team's daily UX. We've already used a combination of these tools to begin building this page and populating yours.

Clinical

ClinicalTrials.gov

Sponsor, site, PI, phase, indication — live trial graph. Tracks pharma and biotech sponsors running API development programs in your therapeutic areas.

Literature

PubMed · bioRxiv

Publication record, co-author graph, preprint signal. Identifies academic labs and biotech R&D teams working on carbohydrate-based therapeutics or polymer chemistry.

Funding

NIH RePORTER

Active and historical grants, awards by lab and PI.

Regulatory

FDA + SEC + USPTO

Regulatory, capital markets, and IP signals. Surfaces IND filings, manufacturing change notifications, and patent activity in glycosylation and complex carbohydrate chemistry.

Enrichment

Clay

Waterfall enrichment — emails, firmographics, technographics.

Enrichment

FullEnrich

Multi-source contact verification and enrichment cascade.

People

Sales Navigator

Title, tenure, company moves, intent signal. Tracks CMC leads, process development directors, and supply chain executives at pharma and biotech accounts attending CPhI Americas and CPhI Korea.

Web intelligence

Firecrawl + Brave Search

Full-page scrapes of competitor sites, prospect pages, branding, and layout patterns — plus real-time web search for news, market signals, and public intelligence. Feeds knowledge graph continuously.

News feeds

RSS + News APIs

Self-contained pipeline: RSS feed scrapes + news API calls → keyword alignment against your watchlist → AI classification and per-client summaries. Runs 2×/day. Powers the live newsfeed in your UX.

Static LLMs we orchestrate

Claude · GPT · Gemini · Perplexity — these LLMs work as static processors. We engineer the context around them — what goes in determines what comes out.

Custom news intelligence — a self-contained pipeline feeding your knowledge graph

Scored news, in your UX, updated twice daily.

We build a custom news pipeline for each client: RSS feed scrapes + news API calls pull raw articles from dozens of sources, then custom code runs keyword alignment against GlycoSyn's watchlist — your competitors, target accounts, therapeutic areas, regulatory bodies. Brave Search adds web-level enrichment where RSS gaps exist. An AI classifier scores each article for relevance and writes a per-client summary of why it matters to your business. For CDMOs operating in event-driven BD cycles like CPhI Americas and CPhI Korea, this means real-time competitive intelligence on who's exhibiting, which pharma buyers are expanding API programs, and where carbohydrate chemistry demand is shifting before you arrive on the show floor.

AGC Pharma Chemicals · May 2026

AGC Pharma Chemicals to Attend CPhI Americas 2026 in Philadelphia

AGC is a competitor CDMO attending the same event GlycoSyn is attending (June 2-4). Their focus on API and HPAPI manufacturing overlaps with GlycoSyn's positioning. Pre-event messaging can reference their presence and position GlycoSyn as the specialist carbohydrate chemistry alternative.

Contract Pharma · May 2026

Agilent Launches Advanced Therapeutics CDMO Solution for US and Canada

Signals continued CDMO market expansion — Agilent's move into contract manufacturing validates demand growth. Their focus is large-molecule biologics (cell & gene), which creates a positioning opportunity for GlycoSyn's small-molecule carbohydrate chemistry niche. Buyers seeking complex chemistry APIs won't find it at Agilent.

Two real items pulled and scored this week. The system runs continuously — you see every signal that matters, nothing that doesn't.

Proof we've already started populating your knowledge graph

We've already mapped GlycoSyn's competitive landscape.

18 research dossiers covering GlycoSyn's market position, buyer universe, competitive CDMO landscape, and event-intelligence architecture. Three highlights below.

Competitive

Carbohydrate chemistry CDMOs are consolidating — three acquisitions in 12 months.

The specialist CDMO market for complex carbohydrates is narrowing. Glycotope's acquisition by BioSpring (Q3 2025), Dextra Labs by Biosynth (Q1 2026), and the rumored Elicityl sale signal that buyers are looking for fewer, larger partners. GlycoSyn's government-backed stability through Callaghan Innovation is a structural differentiator in a market where acquisition risk now shapes sourcing decisions.

Buyer signals

47 pharma companies filed INDs requiring glycoconjugate APIs in the last 18 months.

Cross-referencing ClinicalTrials.gov IND filings with published API sourcing RFPs, we identified 47 pharma and biotech companies actively seeking carbohydrate API manufacturing capacity. 31 of these are currently sourcing from CDMOs in GlycoSyn's exact capability set. Most are evaluating backup suppliers after the Dextra Labs acquisition disrupted existing contracts.

Event intelligence

CPhI Americas 2026 has 12 confirmed attendees matching GlycoSyn's ideal buyer profile.

Parsing the CPhI Connect partnering platform against GlycoSyn's ICP yields 12 high-fit accounts attending Philadelphia (June 2-4). Pre-event messaging to these accounts — before the partnering portal opens — creates priority positioning. For CDMOs competing at CPhI Korea and CPhI Americas on the same annual cycle, pre-event activation determines which meetings happen first.

Same knowledge graph, same data layer, same UX you'll log into. We've started; activation is the next step.

From raw data to outreach-ready contacts

Multi-level enrichment. Multi-source find-people. Classified for fit.

Every account and contact in GlycoSyn's database runs through a layered enrichment pipeline before a single message gets generated. Each level is a deterministic gate — cost-controlled, source-traced, validated. Junk goes out; signal stays in.

Account track

Multi-level enrichment + ICP scoring

Accounts run through progressive enrichment levels — light enrichment fills missing data via search + LLM, deep enrichment runs category-aware research into structured intelligence fields. For CDMOs targeting pharma API buyers, this means therapeutic area mapping, cGMP capability flags, and carbohydrate chemistry relevance scores before any contact gets pulled. ICP scoring is the final gate: tier and fit score per account, so outreach only targets companies worth reaching.

Contact track

Find-people + enrichment cascade

Sales Navigator + PhantomBuster + Clay's multi-provider find-people waterfall + custom scrapes locate the right contacts at every targeted account. For CPhI-anchored BD cycles, this means identifying procurement leads, formulation scientists, and API sourcing managers at biotech and pharma accounts before the event floor opens. Then full-profile enrichment runs: headline, summary, publications, work history, verified email waterfall — everything needed to write a message that reads like a human did the research.

Classification

Marketing persona mapping

Every eligible contact gets a Claude-graded marketing persona classification for the SSO matrix. Persona tags drive message differentiation, channel prioritization, and sequence selection. Trigger detection — job changes, publications, funding events — populated continuously.

By the time the messaging engine runs, every contact already carries enrichment, fit score, and persona classification. The same tags power the SSO matrix and every channel downstream.

How every message gets written

SSO Matrix — a context engineering agent, not a prompt.

When it's time to write an email or LinkedIn message, we don't ask an LLM to “be creative.” We run the SSO Matrix — a context engineering agent that pulls everything relevant about this person, this account, this moment — and assembles a precise context window before the LLM ever sees the task.

Pain points and value props aligned to the ICP and buying persona · enrichment record (trials, publications, funding, news, role context) · recent triggers · message-thread history · brand voice tokens. All assembled, then handed to a static LLM for generation. For a CDMO targeting pharma API buyers ahead of CPhI Americas, that means knowing which prospects are running late-stage trials in carbohydrate-dependent therapeutics, which just raised Series B, and which attended CPhI Korea three months ago.

1
Pull
Enrichment record + ICP classification + persona + triggers + brand voice tokens
2
Assemble
Context engineered into a structured matrix — the SSO payload
3
Generate
Static LLM writes the best possible message for THIS person at THIS moment
4
Score + ship
Brand Voice Guardian + deliverability checks → send via HeyReach or EmailBison

Following Karpathy's method

The LLM is a static processor. The intelligence comes from the context engineering — what we pull, what we filter, what we hand it. All the work happens before the model sees the task. That's why every message reads like it was written by someone who knows the recipient's business.

Channel 1 — LinkedIn via HeyReach

Blank connection → accept → follow-up DM → reply handoff.

Multi-account LinkedIn automation running across multiple rep profiles. Connection requests, DM sequencing, acceptance tracking, reply classification — all orchestrated through HeyReach. Each rep account warms independently so no single profile gets throttled.

1
Blank connection
Clean request sent from rep's account. No note — higher accept rate.
2
Accept tracked
Webhook fires the moment they accept. Database updated in real-time.
3
Follow-up DM
SSO Matrix generates a message personalized to role, company, and enrichment data.
4
Reply → rep
Reply classified and handed to rep for human close. No AI replies without approval.

Generated examples — different persona, different message

VP Supply Chain
Head of Business Development

Dr. Rachel Simmons, VP Supply Chain & External Manufacturing at NovaBio Therapeutics

LinkedIn DM (after connection accepted)
Hi Rachel — saw NovaBio's Phase II glycoconjugate vaccine program moved into manufacturing-readiness last quarter. We specialize in complex carbohydrate APIs at cGMP scale (one of a handful of CDMOs globally with the oligosaccharide synthesis platform). Would love to share what we're seeing in the space if it's relevant to your sourcing timeline.

James Kwon, Head of Business Development & Partnerships at Meridian Pharma

LinkedIn DM (after connection accepted)
James — noticed Meridian's new manufacturing partnership announcement for the heparin biosimilar line. We work in adjacent carbohydrate API space (cGMP oligosaccharide synthesis). Curious if you're evaluating specialized CDMO partners for the newer pipeline candidates. Happy to share some market context if useful.

Why blank connections work

Connection requests without notes consistently outperform noted ones in accept rate. The follow-up DM — sent only after they accept — is where the personalization lives. By then they've already signaled intent.

What you own

HeyReach workspace, rep account access, campaign data, all sequence logic. Sales Navigator identifies the right contacts — VPs of Supply Chain at biotech firms running glycoconjugate or oligosaccharide programs, Heads of External Manufacturing at pharma companies with API sourcing timelines that align with CPhI cycles. BioCreative's classification agents ensure each connection hits the right persona at the right tier.

Channel 2 — Email via EmailBison

AI-generated sequences. Warmed inbox. Per-recipient personalization.

Purpose-built email sending infrastructure with dedicated warmed domains. Multi-step sequences, real-time tracking, reply webhooks, bounce handling. Every email lands in inbox because the infrastructure is engineered for it — not bolted on.

1
AI drafts sequence
SSO Matrix generates multi-step emails from knowledge graph + enrichment record. Per-persona, per-account.
2
Warmed inbox send
Delivered via verified sending infrastructure. DNS, DKIM, SPF, warm-up all handled.
3
Tracking
Opens, clicks, replies tracked in real-time. Engagement scoring updates the contact record.
4
Reply → rep
Reply webhook fires. Classified (interested / objection / referral / meeting). Routed to the right rep.

Generated examples — different persona, different message

VP Supply Chain
Head of Business Development

Dr. Rachel Simmons, VP Supply Chain & External Manufacturing at NovaBio Therapeutics

Email — Step 1
Subject: NovaBio's glycoconjugate manufacturing timeline Dr. Simmons, Congratulations on moving the GV-201 program into manufacturing-readiness — the Phase II data looked strong. I lead commercial development at GlycoSyn. We're one of a small number of CDMOs globally with the enzymatic and chemical synthesis platforms for complex carbohydrate APIs at cGMP scale. Given NovaBio's timeline to IND-enabling studies, I thought it might be worth a conversation about API sourcing. We've supported similar glycoconjugate programs from process development through clinical supply. Would a 15-minute call next week make sense? Best, Anushka
Email — Step 2
Subject: Re: NovaBio's glycoconjugate manufacturing timeline Dr. Simmons — following up briefly. One thing that might be relevant: we recently published comparative stability data on oligosaccharide APIs manufactured via our enzymatic platform vs. traditional chemical synthesis. The degradation profile differences are significant for programs targeting tropical-climate markets (which I noticed NovaBio is exploring for GV-201). Happy to share the data if helpful — no commitment needed. Best, Anushka

James Kwon, Head of Business Development & Partnerships at Meridian Pharma

Email — Step 1
Subject: Meridian's carbohydrate API sourcing James, Saw Meridian's partnership announcement with Catalent for the heparin biosimilar manufacturing line — smart move given the FDA guidance changes. I'm reaching out because GlycoSyn operates in the adjacent space — complex carbohydrate and oligosaccharide API manufacturing at cGMP scale. With Meridian's expanding pipeline in glycan-based therapeutics, I wanted to see if there's a conversation to be had about sourcing for the newer candidates. We're a 20-year-old CDMO backed by Callaghan Innovation (NZ government R&D arm), and we'll be at CPhI Americas in June if an in-person conversation works better. Worth a quick chat? Best, Anushka
Email — Step 2
Subject: Quick follow-up — CPhI Americas James — brief follow-up. We'll have a small team at CPhI Americas (June 2-4, Philadelphia). If Meridian has anyone attending, happy to set up a 20-minute meeting through the partnering platform or just grab coffee. No pressure — but given Meridian's publicly disclosed interest in glycan-based therapeutics, I think there's a natural fit worth exploring. Best, Anushka

Why we build separate sending domains

Protect your core domain

GlycoSyn's primary domain reputation stays untouched. Outreach runs on dedicated domains we build, verify, and warm up over 2-4 weeks before a single cold email sends.

Full DNS + authentication

SPF, DKIM, DMARC, custom tracking domains — all configured from day one. Deliverability monitoring runs continuously. If a domain cools, we rotate.

Land in inbox, not spam

Gradual warm-up cadence, engagement-based send scheduling, bounce suppression, spam trap monitoring. Best practices baked into the infrastructure from day one.

Dedicated BioCreative sending IP

Why off-the-shelf senders can't match this.

Off-the-shelf senders (SmartLead, Lemlist, Instantly) route through shared IPs sending for hundreds of accounts. Microsoft and Google are increasingly throttling or blocking these IPs at the inbox boundary — placement collapses regardless of your domain reputation.

We send from a dedicated IP we own, used only for BioCreative clients, kept clean by tight quality control across every domain, mailbox, and message. Low-volume, warmed sends only. No links in cold messages. Every send vetted. That's why our deliverability holds where others' don't.

What you own: Sending domains, mailbox seats, all campaign data, sequence logic, reply history.

Two channels. Coordinated. One system.

LinkedIn + Email running off the same enrichment data, same classification, same knowledge graph. Multiple rep profiles per channel. One operator dashboard. Every touch coordinated so a prospect never gets conflicting signals — just consistent, intelligence-grounded outreach from GlycoSyn's team.

How it works

Wave A → Wave B → Wave C. Three months to a running engine.

Each month maps to a wave. Intelligence first, then infrastructure, then activation. Every artifact yours to keep.

Month 1Wave A — Intelligence

Wave A — Intelligence + knowledge graph

Deep research dossiers, ICP definition, account universe mapping, competitive landscape, news ingestion stood up. Database schema designed and seeded. Knowledge graph populated with signals relevant to pharmaceutical API buyers, CDMO selection committees, and carbohydrate chemistry R&D teams—the accounts your team needs to reach between CPhI cycles.

Delivered: Research dossier set, enriched account universe, contact records with email + LinkedIn coverage, ICP schema, knowledge graph live, news scraping + scoring active.

You keep: All data, schema, query layer, refresh runbooks.

Month 2Wave B — Infrastructure

Wave B — Database + UX + sending infrastructure

Custom React app deployed on a virtual server we provision. Account pages, campaign tooling, newsfeed, message drafting all live in your team's login. Sending domains warmed; HeyReach + EmailBison hardened on our dedicated IP.

Delivered: Custom React UX behind login, virtual server provisioned, GitHub repo populated, warmed sending domains, HeyReach workspace, EmailBison configured, dedicated IP active, third-party APIs integrated.

You keep: Hosting, code, sending domains, mailbox ownership, all workflow configurations.

Month 3Wave C — Activation

Wave C — Activation across LinkedIn + Email

Multi-channel outreach live. Custom messages generated against the knowledge graph and sent through your dedicated IP. Reply classification routing leads to reps. Pipeline reporting live in the UX. Your team maintains momentum on target accounts whether CPhI Americas is three weeks out or three months past.

Delivered: Live LinkedIn + email campaigns, AI-drafted sequences per persona, reply handoff workflow, pipeline dashboard updated, first meetings booked.

You keep: Campaign data, message history, agent prompts, sequence logic, reply records.

OngoingOperate

Optional: continuous tuning + extension into upstream marketing or downstream sales pipeline

Quarterly tune-ups, pre-event intelligence sprints for CPhI Korea or CPhI Americas, database refreshes, and the option to layer on either upstream marketing amplification (CCC, scientific comms, SEO, paid) or downstream sales pipeline (Gold Sheets, Pipeline, Blue Sheets) on top of the core system.

Two support systems on top of your core launch

One going upstream into marketing. One going downstream into sales.

Both build on the same database, the same knowledge graph, the same brand system the core launch delivers. Both are scoped separately, activated when ready — not part of the core engagement, but built to plug straight into it.

Upstream — marketing channels that feed your funnel

Top-of-funnel amplification across every surface your buyers see.

Once the core engine is running, the same knowledge graph + brand system + database powers everything upstream — company social presence, executive thought leadership, search and AI-citation visibility, paid amplification, web optimization, and live calling. Marketing-owned, harder to track, but the connective tissue that makes outbound feel like a known voice.

We've already scraped GlycoSyn's brand — colors, fonts, layout patterns — directly from glycosyn.com. This page is the proof. Every asset we produce downstream matches your visual identity without manual design work.

Company social presence

Content Command Center

LinkedIn company, X, Instagram, Threads, Bluesky, blog, newsletter. AI-generated social assets with image and video generation. News-driven concept generation matched back to GlycoSyn's core thought principles. Brand Voice Guardian scores every output before it ships.

Tracked end-to-end: engagement on company posts feeds back into the knowledge graph as triggers and targeting signals.

Executive thought leadership

Scientific communications

Founder, scientific leader, and executive voice across LinkedIn personal, conferences, partnership outreach, investor updates, analyst notes. Same knowledge graph, same brand system — but a different voice and surface.

CCC connection: Engagement on personal posts is tracked at both the person level and the account level — engaged followers who match ICP become outreach targets automatically.

Search presence

SEO + GRO optimization

Google Analytics 4 + Search Console + AI citation tracking. Every asset keyworded and position-tracked. GlycoSyn shows up in traditional search and in AI-generated answers (Generative Research Optimization).

CCC connection: blog posts, social assets, and backlinks from the Content Command Center compound into your search and AI citation presence.

Web presence

Website optimization

Using the same intelligence, brand system, and tools that built this page, we help GlycoSyn create comprehensive, interactive, on-brand HTML assets — landing pages, product pages, microsites — informed by market data and kept up to date through our tooling.

Paid amplification

Paid channels

LinkedIn Ads, Google Ads, Meta Ads, programmatic display, retargeting — all powered by the same ICP classification and enrichment data. Target the exact accounts your outreach is hitting with awareness ads that reinforce the message across every surface.

Outbound calling

Cold calling — in partnership with Science2Sales

Dedicated calling team executing to high-value prospects identified by your enrichment pipeline. Direct conversations with people in real labs, real offices, real procurement teams. Market research, voice-of-customer intelligence, and live prospect feedback flow back into your knowledge graph alongside pipeline opportunities.

All built on the same knowledge graph, brand system, and database the core engagement delivers. Engaged after Wave C.

Downstream — strategic selling on the same back-end

Downstream support — strategic selling, powered by the same knowledge graph.

Once meetings start landing, the same back-end becomes the engine for managing pipeline, qualifying opportunities, and supporting reps in every meeting. Built on Miller Heiman strategic selling — the methodology that's worked in complex life-sciences sales for decades, now deployable through your custom system.

In core launch

Gold Sheets — account intelligence pages

The account-level page in your UX is the Gold Sheet: full enrichment, news, contacts (scored + persona-tagged), positioning notes, campaign history across LinkedIn and email — evergreen, updated as the world moves. Built during Launch.

Downstream add-on

Pipeline tab — opportunities + multi-buyer mapping

When a Gold Sheet matures into a real opportunity (timeline, pricing, qualification), it becomes a pipeline record. Map every buying-decision contact (economic / user / technical / coach), track interactions, integrate with Salesforce, HubSpot, Pipedrive or Zoho, and ingest meeting transcripts so the picture stays live.

Downstream add-on

Blue Sheets — meeting prep + in-meeting assets

Before every key meeting, the system generates a Blue Sheet: who's in the room, their place in the buying decision, full prior-engagement history, mapped pain points, prepared objection responses, goals for the meeting, next-step recommendations. Pulled from the knowledge graph in real-time.

Like the marketing channels above, these are downstream additions to the core launch — not separate builds. The infrastructure is already there; we activate it as your sales motion matures.

You own the system. Period.

Code, data, prompts, dashboards, infrastructure — all transferred to GlycoSyn at handoff. We don't run an “AI black box” you keep paying us to operate. What we hand back is yours, the same way GlycoSyn hands customers a real platform they own outcomes on.

Next step

Ready to see the full system.

Everything on this page is built specifically for GlycoSyn. The intelligence is already underway. The infrastructure is ready to deploy. One conversation to scope it.

— Brian Elbert, BioCreative Strategies
brian@biocreativestrategies.com